查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1999479

发炎性肠道疾病治疗市场：2026-2032年全球市场预测（依治疗方法、给药途径、剂型、应用、最终使用者、分销管道和病患类型划分）

Inflammatory Bowel Disease Treatment Market by Treatment Type, Route Of Administration, Formulation Type, Application, End-User, Distribution Channel, Patient Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，发炎性肠道疾病治疗市场价值将达到 209.5 亿美元，到 2026 年将成长至 219.5 亿美元，到 2032 年将达到 294.7 亿美元，复合年增长率为 4.99%。

主要市场统计数据
基准年 2025 209.5亿美元
预计年份：2026年 219.5亿美元
预测年份 2032 294.7亿美元
复合年增长率 (%) 4.99%

对影响发炎性肠道疾病治疗生态系统的新兴趋势和关键驱动因素进行全面概述。

发炎性肠道疾病 (IBD) 涵盖了频谱复杂的慢性胃肠道疾病，其特征是反覆发炎、患者患病率高，且迫切需要更有效的治疗方法。近年来，先进生物製药、精准医疗方法以及不断增长的真实世界数据的融合，彻底改变了我们对该疾病病理生理学和治疗模式的理解。随着分子分型和创新终点指标在临床试验中越来越广泛的应用，从药物研发到医疗保健系统等相关人员都在重新思考其策略，以最大限度地掌握新的机会。

发炎性肠道疾病领域正在发生变革性变化，重新定义研究、治疗方法和患者预后。

发炎性肠道疾病领域正经历着一场根本性的变革，这主要得益于标靶免疫学和再生医学的突破性进展。过去，小分子药物和皮质类固醇占据主导地位，但如今市场正转向精准靶向的生物製剂，例如整合素受体拮抗剂和白细胞介素抑制剂，这些药物具有更高的安全性和有效性。同时，基因治疗载体、微生物组调节剂和干细胞移植等先进治疗方法也正进入后期研发阶段，可望透过恢復黏膜完整性和免疫稳态，实现持续缓解。

预计 2025 年美国关税对 IBD 治疗领域疗法创新和市场进入的累积影响。

美国计划于2025年调整关税政策，可能会对发炎性肠道疾病（IBD）治疗药物的供应链和成本结构产生广泛影响。关键原料和活性药物成分进口关税的提高，可能迫使製造商调整筹资策略，承担额外成本，并影响价格谈判和报销协商。因此，决策者需要密切关注政策动态，并探索替代原料来源和本地生产伙伴关係，以降低成本上升的风险。

細項分析的详细信息，以明确治疗方法、给药途径、剂型、用途、最终用户和患者人口统计特征。

发炎性肠道疾病 (IBD) 治疗市场已从多个维度进行分析，旨在识别关键机会和未满足的需求。根据治疗类型，研究工作涵盖了从氨基水杨酸盐、皮质类固醇和免疫抑制剂等基础小分子药物到肿瘤坏死因子抑制剂、白细胞介素抑制剂和整合素受体拮抗剂等前沿生物製药。此外，基因疗法（旨在重置免疫调节）、微生物组调变器（旨在恢復肠道菌群平衡）以及干细胞疗法（专注于再生受损肠道组织）等先进治疗方法进一步丰富了治疗方案。对于难治性病例，手术介入仍然至关重要，包括切除术、肠切除术和狭窄成形术等，这些手术均需根据复杂的解剖结构进行调整。

区域洞察：揭示美洲、欧洲、中东和非洲以及亚太地区发炎性肠道疾病治疗领域的独特成长要素和病患可及性趋势

区域趋势正以不同的方式影响发炎性肠道疾病（IBD）的治疗模式。在美洲，完善的医疗基础设施和成熟的报销机制促进了新治疗方法的快速普及。患者权益组织和临床网络正在提高公众对疾病的认知，并支持早期诊断和长期治疗方案的依从性。然而，新的挑战包括如何审查高价生物製药的支付方，以及如何透过全面的患者登记资料来证明其在实际临床应用中的价值。

公司简介和竞争定位，重点关注炎症性肠道疾病治疗领域的创新路径和市场领导地位。

领先的製药和生物技术公司正采取多元化策略，以巩固其在发炎性肠道疾病（IBD）领域的地位。老牌主要企业正透过新一代抗体结构和生物相似药开发项目，强化其生物製剂产品系列。同时，新兴创新者正利用先进的治疗平台，促进基因疗法候选药物和基于微生物组的干预措施的合作开发。大型企业与灵活敏捷的生物技术公司之间的合作，透过整合在製程开发和临床营运方面的互补专长，加速了后期临床试验的进程。

为推动 IBD 的永续成长、改善患者预后以及加强关键相关人员。

产业领导企业应优先投资于针对疾病潜在机制的差异化治疗方法，例如具有更高标靶特异性和更持久疗效的新一代生物製剂。同时，将数位健康解决方案整合到临床试验通讯协定和上市后监测中，可以促进以患者为中心的参与，并产生真实世界数据（REW），从而支持医保报销谈判。此外，与包括学术研究机构、患者权益组织和合约开发组织（CDO）在内的广泛相关人员开展合作，将加速转化研究并简化与监管机构的沟通。

采用稳健的调查方法，结合多方面的资料收集、定性和定量分析以及严格的检验过程。

本研究采用多方面方法，结合广泛的二手资料回顾和透过对行业高管、临床医生和支付方进行深度访谈而获得的第一手资讯。二手研究涵盖同行评审文章、监管申报文件、临床试验资料库和行业白皮书，从而对治疗机制、竞争格局和市场准入趋势建立了扎实的基础理解。第一手研究包括与全球意见领袖进行结构化讨论，揭示了临床应用驱动因素和患者管理挑战的细微观点。

综合关键研究成果和未来展望，为不断发展的发炎性肠道疾病治疗市场的相关人员提供全面结论。

本执行摘要整合了影响发炎性肠道疾病 (IBD) 治疗市场的关键趋势，涵盖了从新型疗法和先进治疗方法到预期价格调整的策略意义等各个方面。细分市场分析揭示了产品在治疗类型、给药途径、剂型和患者族群等方面实现差异化的关键途径。区域洞察重点关注了不同的成长驱动因素，包括美洲成熟的医保报销环境、欧洲、中东和非洲 (EMEA) 地区的监管协调工作以及亚太地区成长要素的激增。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 发炎性肠道疾病治疗市场（依治疗方法）

  • 先进治疗方法
    • 基因治疗
    • 微生物组调节剂
    • 干细胞疗法
  • 生物製药
    • 整合素受体拮抗剂
    • 白细胞介素抑制剂
    • TNF抑制剂
  • 小分子药物
    • 氨基水杨酸製剂
    • 皮质类固醇
    • 免疫抑制剂
  • 手术治疗
    • 结肠造口术
    • 切除
    • 狭窄成形术

第九章 发炎性肠道疾病治疗市场：依给药途径划分

  • 注射药物
    • 静脉
    • 皮下
  • 口服
  • 直肠

第十章：以剂型分類的发炎性肠道疾病治疗市场

  • 液体
    • 口服液体药物
    • 悬浮液
  • 注射剂
  • 固态剂型
    • 咀嚼片
    • 缓释片

第十一章 发炎性肠道疾病治疗市场：依应用领域划分

  • 克隆氏症
  • 病因不明的结肠炎
  • 溃疡性大肠炎

第十二章 发炎性肠道疾病治疗市场：依最终使用者划分

  • 诊所
  • 居家照护设施
  • 医院

第十三章 发炎性肠道疾病治疗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十四章 发炎性肠道疾病治疗市场病患细分

  • 成人
  • 老年人
  • 儿童

第十五章 发炎性肠道疾病治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章 发炎性肠道疾病治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 发炎性肠道疾病治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章：美国发炎性肠道疾病治疗市场

第十九章 中国发炎性肠道疾病治疗市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Abivax
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Eli Lilly and Company
  • Entera Bio Ltd.
  • FutureGen Biopharmaceutical（Beijing）Co., Ltd.
  • GlaxoSmithKline PLC
  • Ironwood Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Morphic Therapeutic, Inc.
  • Nestle SA
  • OPKO Health, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharma Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • TScan Therapeutics, Inc.
  • UCB SA
  • Viatris Inc.
  • Zealand Pharma A/S
Product Code: MRR-563BF1FCFF1E

The Inflammatory Bowel Disease Treatment Market was valued at USD 20.95 billion in 2025 and is projected to grow to USD 21.95 billion in 2026, with a CAGR of 4.99%, reaching USD 29.47 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 20.95 billion
Estimated Year [2026] USD 21.95 billion
Forecast Year [2032] USD 29.47 billion
CAGR (%) 4.99%

A Comprehensive Introduction to Emerging Dynamics and Critical Drivers Shaping the Inflammatory Bowel Disease Treatment Ecosystem

Inflammatory bowel disease encompasses a complex spectrum of chronic gastrointestinal disorders characterized by relapsing inflammation, significant patient morbidity, and an urgent need for more effective therapies. In recent years, the convergence of advanced biologic agents, precision medicine approaches, and expanding real-world data has transformed our understanding of disease pathophysiology and treatment paradigms. As clinical trials increasingly embrace molecular subtyping and innovative endpoints, stakeholders from pharmaceutical developers to healthcare systems are realigning their strategies to capitalize on emerging opportunities.

Furthermore, dynamic shifts in patient demographics, regulatory frameworks, and reimbursement landscapes are elevating the demand for differentiated therapeutic solutions. Healthcare providers are seeking treatments that offer sustained remission with minimized safety concerns, while payers are scrutinizing value propositions to manage the economic burden of chronic immune-mediated diseases. As a result, industry participants are deploying multidisciplinary research and forging cross-sector collaborations to accelerate the development of pioneering modalities that aim to redefine standards of care in inflammatory bowel disease.

Transformational Shifts Redefining Research, Treatment Modalities, and Patient Outcomes in the Evolving Inflammatory Bowel Disease Landscape

The inflammatory bowel disease landscape has undergone fundamental transformations driven by breakthroughs in targeted immunology and regenerative medicine. Historically dominated by small molecule drugs and corticosteroids, the market has shifted toward precision-targeted biologics such as integrin receptor antagonists and interleukin inhibitors, which offer superior safety and efficacy profiles. Concurrently, advanced therapies-including gene therapy vectors, microbiome modulators, and stem cell transplantation-are entering late-stage development, promising durable remission through restoration of mucosal integrity and immune homeostasis.

Moreover, digital health innovations and remote monitoring tools are enabling real-time disease management and empowering patients to actively participate in therapy regimens. Advances in telemedicine platforms are streamlining follow-up care, reducing hospitalizations, and improving adherence. In parallel, evolving regulatory pathways now accommodate breakthrough designations and adaptive trial designs, expediting the translation of laboratory discoveries into clinical interventions. Together, these shifts are redefining competitive dynamics and creating fertile ground for next-generation therapies that target the root causes of inflammatory bowel disease.

Assessing the Projected Cumulative Impact of 2025 United States Tariffs on Therapeutic Innovation and Market Accessibility in IBD Care

Anticipated adjustments in United States tariff policies for 2025 carry far-reaching implications for the inflammatory bowel disease therapy supply chain and cost structures. Increased import duties on key raw materials and active pharmaceutical ingredients may compel manufacturers to reassess sourcing strategies or absorb additional expenses, potentially affecting pricing negotiations and reimbursement discussions. Consequently, decision makers must monitor policy developments closely and explore alternative materials procurement or localized production partnerships to mitigate cost escalations.

Furthermore, tariff-induced pressures could accelerate interest in domestic biomanufacturing capabilities, spurring investments in flexible facilities and contract development organizations to localize critical manufacturing processes. Such a shift would not only buffer companies against external trade fluctuations but also enhance supply chain resilience. At the same time, collaborations with regulatory bodies and industry coalitions will be essential to navigate potential compliance hurdles and secure timely approvals. By proactively addressing these tariff dynamics, stakeholders can safeguard market access and maintain momentum in bringing innovative IBD therapies to patients.

Deep Dive into Segmentation Insights Revealing Treatment Modalities, Administration Routes, Formulation Types, Applications, End-Users, and Patient Demographics

The inflammatory bowel disease treatment market is dissected across multiple dimensions to reveal critical opportunities and unmet needs. Based on treatment type, research efforts extend from foundational small molecule drugs such as aminosalicylates, corticosteroids, and immunosuppressants to cutting-edge biologic classes including tumor necrosis factor inhibitors, interleukin blockers, and integrin receptor antagonists. Advanced therapies further diversify the landscape through gene therapy constructs designed to reset immune regulation, microbiome modulators aiming to restore gut flora balance, and stem cell therapies focused on regenerating damaged intestinal tissue. Surgical interventions remain integral for refractory cases, with procedures ranging from ostomy creation to resections and strictureplasties tailored to complex anatomical challenges.

In addition, administration route segmentation highlights the strategic relevance of injectable formulations delivered intravenously or subcutaneously, complemented by patient-preferred oral and rectal therapies that foster adherence. Formulation type analysis underscores the distinction between liquid formulations, such as oral solutions and suspensions, versus solid dosage forms including chewable and extended release tablets, alongside specialized parenteral preparations. Treatment applications concentrate on Crohn's disease, indeterminate colitis, and ulcerative colitis, each presenting unique pathophysiology and therapeutic endpoints. Moreover, end-user settings span traditional hospital environments, specialized clinics, and increasingly vital home care scenarios that support self-administration. Distribution channels cut across hospital pharmacies, online platforms, and retail outlets to optimize patient access. Finally, patient type considerations differentiate adult, geriatric, and pediatric populations, ensuring that product development and care models address distinct safety, dosing, and compliance factors across life stages.

Regional Insights Unveiling Distinct Growth Drivers and Patient Access Dynamics across the Americas, EMEA, and Asia-Pacific in IBD Therapeutics

Regional dynamics shape the inflammatory bowel disease treatment landscape in distinct ways. In the Americas, robust healthcare infrastructure and established reimbursement frameworks facilitate rapid adoption of novel therapies. Patient advocacy groups and clinical networks further drive awareness, supporting early diagnosis and adherence to long-term treatment regimens. However, emerging challenges include payer scrutiny of high-cost biologics and the imperative to demonstrate real-world value through comprehensive patient registries.

In Europe, the Middle East, and Africa, a mosaic of regulatory environments influences market entry strategies. Harmonization efforts across the European Union streamline approval pathways, whereas variable reimbursement policies in the Middle East and Africa necessitate adaptive pricing models. Local manufacturing partnerships and public-private initiatives are increasingly critical to improve therapy availability and address regional disease burdens. Across Asia-Pacific, escalating IBD incidence, bolstered by lifestyle shifts and urbanization, is prompting governments to prioritize chronic disease management. Incentives for domestic biotech innovation and strategic licensing agreements are propelling new entrants into this high-growth arena, while generics and biosimilars play an essential role in expanding patient access.

Strategic Company Profiles and Competitive Positioning Highlighting Innovation Pathways and Market Leadership in Inflammatory Bowel Disease Treatment

Leading pharmaceutical and biotechnology companies are pursuing diverse strategies to secure their positions in the inflammatory bowel disease arena. Established players are enhancing their biologics portfolios with next-generation antibody constructs and biosimilar development programs. Meanwhile, emerging innovators are capitalizing on advanced therapy platforms, forging alliances to co-develop gene therapy candidates and microbiome-based interventions. Collaborative ventures between large-cap firms and nimble biotechs are accelerating late-stage trials, leveraging complementary expertise in process development and clinical operations.

Competitive positioning is also influenced by robust intellectual property protection and strategic patent litigation, as companies seek to extend exclusivity periods for high-value assets. In parallel, royalty monetization agreements and divestitures of non-core assets are optimizing balance sheets, enabling reinvestment in high-potential pipelines. As regulatory agencies exhibit greater flexibility through accelerated pathways and conditional approvals, organizations equipped with adaptive clinical trial designs and real-world evidence capabilities will gain a decisive advantage. Overall, the interplay of M&A activity, co-development partnerships, and innovation-driven collaboration is reshaping the competitive terrain.

Actionable Strategic Recommendations to Drive Sustainable Growth, Enhance Patient Outcomes, and Foster Collaboration among Key Stakeholders in IBD

Industry leaders should prioritize investment in differentiated modalities that address underlying disease mechanisms, such as next-generation biologics with enhanced targeting specificity and durable response profiles. In parallel, integrating digital health solutions into clinical trial protocols and post-market surveillance can foster patient-centric engagement and generate real-world evidence to support reimbursement negotiations. Furthermore, cultivating multi-stakeholder collaborations-including alliances with academic research centers, patient advocacy groups, and contract development organizations-will accelerate translational research and streamline regulatory interactions.

Moreover, supply chain resilience should be fortified by diversifying manufacturing footprints and exploring regional production partnerships to mitigate tariff impacts and logistical disruptions. Organizations are encouraged to adopt modular facility designs and flexible contract manufacturing strategies to adapt to evolving demand patterns. Lastly, a concerted focus on emerging markets-supported by localized value demonstration and tiered pricing frameworks-will unlock high-growth opportunities while advancing equitable access to transformative therapies.

Robust Research Methodology Combining Multi-Source Data Collection, Qualitative and Quantitative Analyses, and Rigorous Validation Processes

This research integrates a multi-source approach, combining extensive secondary data review with primary insights gathered through in-depth interviews with industry executives, clinicians, and payers. Secondary research encompassed peer-reviewed publications, regulatory filings, clinical trial databases, and industry white papers to establish a robust foundational understanding of therapeutic mechanisms, competitive landscapes, and market access dynamics. Primary engagements involved structured discussions with opinion leaders across geographies, uncovering nuanced perspectives on clinical adoption drivers and patient management challenges.

Quantitative analysis was conducted using proprietary data models that triangulate findings across independent datasets, ensuring rigorous validation of thematic conclusions. Qualitative thematic coding was applied to interview transcripts to identify recurring trends, unmet clinical needs, and strategic imperatives. Iterative validation workshops with domain experts further refined key insights and resolved information gaps. Together, these methodologies provide a comprehensive, reliable, and actionable framework for stakeholders navigating the inflammatory bowel disease treatment arena.

Comprehensive Conclusion Synthesizing Key Findings and Future Outlook for Stakeholders in the Evolving Inflammatory Bowel Disease Treatment Market

This executive summary has synthesized pivotal developments shaping the inflammatory bowel disease treatment market, from emerging therapeutic classes and advanced modalities to the strategic implications of anticipated tariff changes. Segmentation analysis has illuminated critical pathways for product differentiation across treatment types, administration routes, formulation formats, and patient demographics. Regional insights underscore the multiplicity of growth drivers-from mature reimbursement landscapes in the Americas to regulatory harmonization efforts in EMEA and surging demand trajectories in Asia-Pacific.

Competitive intelligence reveals that innovation convergence, strategic partnerships, and agile manufacturing approaches will determine market leadership moving forward. Actionable recommendations emphasize the importance of targeted investment in next-generation therapies, digital health integration, supply chain resilience, and market-specific access strategies. As stakeholders chart their strategies for 2025 and beyond, a proactive, evidence-based approach will be essential to unlocking value, enhancing patient outcomes, and sustaining long-term growth in this dynamic and high-stakes therapeutic domain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Inflammatory Bowel Disease Treatment Market, by Treatment Type

  • 8.1. Advanced Therapies
    • 8.1.1. Gene Therapy
    • 8.1.2. Microbiome Modulators
    • 8.1.3. Stem Cell Therapy
  • 8.2. Biologics
    • 8.2.1. Integrin Receptor Antagonists
    • 8.2.2. Interleukin Inhibitors
    • 8.2.3. TNF Inhibitors
  • 8.3. Small Molecule Drugs
    • 8.3.1. Aminosalicylates
    • 8.3.2. Corticosteroids
    • 8.3.3. Immunosuppressants
  • 8.4. Surgical Procedures
    • 8.4.1. Ostomy
    • 8.4.2. Resection
    • 8.4.3. Strictureplasty

9. Inflammatory Bowel Disease Treatment Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intravenous
    • 9.1.2. Subcutaneous
  • 9.2. Oral
  • 9.3. Rectal

10. Inflammatory Bowel Disease Treatment Market, by Formulation Type

  • 10.1. Liquid Formulations
    • 10.1.1. Oral Solutions
    • 10.1.2. Suspensions
  • 10.2. Parenteral Preparations
  • 10.3. Solid Dosage Forms
    • 10.3.1. Chewable Tablets
    • 10.3.2. Extended Release Tablets

11. Inflammatory Bowel Disease Treatment Market, by Application

  • 11.1. Crohns Disease
  • 11.2. Indeterminate Colitis
  • 11.3. Ulcerative Colitis

12. Inflammatory Bowel Disease Treatment Market, by End-User

  • 12.1. Clinics
  • 12.2. Home Care Settings
  • 12.3. Hospitals

13. Inflammatory Bowel Disease Treatment Market, by Distribution Channel

  • 13.1. Hospital Pharmacies
  • 13.2. Online Pharmacies
  • 13.3. Retail Pharmacies

14. Inflammatory Bowel Disease Treatment Market, by Patient Type

  • 14.1. Adult Population
  • 14.2. Geriatric Population
  • 14.3. Pediatric Population

15. Inflammatory Bowel Disease Treatment Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Inflammatory Bowel Disease Treatment Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Inflammatory Bowel Disease Treatment Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Inflammatory Bowel Disease Treatment Market

19. China Inflammatory Bowel Disease Treatment Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Abbott Laboratories
  • 20.6. AbbVie Inc.
  • 20.7. Abivax
  • 20.8. Amgen Inc.
  • 20.9. Bristol-Myers Squibb Company
  • 20.10. Cipla Limited
  • 20.11. Eli Lilly and Company
  • 20.12. Entera Bio Ltd.
  • 20.13. FutureGen Biopharmaceutical (Beijing) Co., Ltd.
  • 20.14. GlaxoSmithKline PLC
  • 20.15. Ironwood Pharmaceuticals, Inc.
  • 20.16. Johnson & Johnson Services, Inc.
  • 20.17. Merck & Co., Inc.
  • 20.18. Morphic Therapeutic, Inc.
  • 20.19. Nestle S.A.
  • 20.20. OPKO Health, Inc.
  • 20.21. Pfizer Inc.
  • 20.22. Sanofi SA
  • 20.23. Sun Pharma Limited
  • 20.24. Takeda Pharmaceutical Company Limited
  • 20.25. Teva Pharmaceutical Industries Ltd.
  • 20.26. TScan Therapeutics, Inc.
  • 20.27. UCB S.A.
  • 20.28. Viatris Inc.
  • 20.29. Zealand Pharma A/S

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY MICROBIOME MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY MICROBIOME MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY MICROBIOME MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTEGRIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTEGRIN RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTEGRIN RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY AMINOSALICYLATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY AMINOSALICYLATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY AMINOSALICYLATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY OSTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY OSTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY OSTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RESECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RESECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RESECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STRICTUREPLASTY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STRICTUREPLASTY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STRICTUREPLASTY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RECTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RECTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RECTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ORAL SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ORAL SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL PREPARATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL PREPARATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL PREPARATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CHEWABLE TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CHEWABLE TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CHEWABLE TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY EXTENDED RELEASE TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY EXTENDED RELEASE TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY EXTENDED RELEASE TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CROHNS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CROHNS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CROHNS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INDETERMINATE COLITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INDETERMINATE COLITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INDETERMINATE COLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ULCERATIVE COLITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ULCERATIVE COLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADULT POPULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADULT POPULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADULT POPULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GERIATRIC POPULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GERIATRIC POPULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GERIATRIC POPULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PEDIATRIC POPULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PEDIATRIC POPULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PEDIATRIC POPULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. GCC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. GCC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. GCC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 276. GC